novavax nvax - Search News

Order byBest matchMost fresh

Novavax Soars

Novavax: Nuvaxovid FDA Approval Unlocks Several Bullish Stimuli

The approval positions Novavax as the only non-mRNA COVID-19 vaccine with full FDA approval, offering a differentiated alternative amid growing mRNA fatigue.

· 7h

Clinical Advisor · 3h

FDA Approves Novavax’s COVID-19 Vaccine Nuvaxovid

· 2d · on MSN

Novavax Stock Soars on FDA Approval for New COVID-19 Vaccine

F.D.A. Poised to Restrict Access to Covid Vaccines

The Food and Drug Administration will permit Covid vaccines for adults over 65 and those with certain medical conditions in the fall, according to new regulatory standards detailed on Tuesday by agen...

· 18h

· 17h

FDA tightens requirements for COVID vaccine, adding trials for healthy adults

· 1d

Annual COVID-19 Shots For Healthy Younger Adults, Children Will No Longer Be Routinely Approved

FDA may limit future Covid-19 shots to older people and those at risk of serious infection

Millions of healthy adults and kids will likely lose access to updated vaccines under the new criteria.

· 21h

· 3h

FDA plans to limit COVID vaccine to only high-risk people. Who would still be eligible?

· 1d

FDA sets new COVID booster guidelines for healthy adults under 65

1hon MSN

BofA Reiterates Hold Rating on Novavax (NVAX) Stock

BofA analyst Alec Stranahan reiterated a Hold rating on Novavax, Inc. (NASDAQ:NVAX) stock, setting a price target of $10. The approval of Nuvaxovid for use in older and high-risk adults will generate around $175 million in milestone payments from Sanofi during Q3 and an additional $50 million in the second half of

Why Novavax Shares Are Trading Higher By Around 17%; Here Are 20 Stocks Moving Premarket

Novavax shares jumped 16.6% to $7.84 in the pre-market trading session. Here are some other stocks moving in pre-market trading. Markets expect rate cuts — but your earnings don’t have to suffer. Lock in 7.2% until 2028 from ten individual bonds.

Stock Movers Alibaba ADRs, Novavax, Reddit

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies making news on Wall Street.

1don MSN

JPMorgan Maintains Underweight Rating on Novavax (NVAX) Stock Despite Positive News

JPMorgan analyst Eric Joseph reaffirmed an Underweight rating for Novavax Inc. (NASDAQ:NVAX) with a price target of $7. This comes after the Food and Drug Administration (FDA) approved the company’s COVID-19 vaccine,

1BNTX, NVAX : Novavax Wins Limited FDA Nod For COVID Shot—Cleared Only For Seniors...

The U.S. Food and Drug Administration has granted limited approval to Novavax Inc.'s COVID-19 vaccine, restricting its use to people 65 and older and those 12 and up with underlying health conditions that increase risk of severe illness.

Schaeffer's Investment Research2d

Novavax Stock Soars on FDA Approval for COVID Vaccine

In the options pits, NVAX has already seen quadruple the overall options volume it typically sees in an entire session, with 57,000 calls and 13,000 puts exchanged so far. The weekly 5/23 9-strike call is the most active, with new positions opening there.

Stocktwits on MSN1d

FDA Sets New Guidelines For Approving COVID-19 Booster Shots In Healthy Individuals: Moderna, Novavax Stocks Rise

The U.S. Food and Drug Administration (FDA ) leaders said on Tuesday they would adopt a new COVID-19 vaccination regulatory framework, requiring new clinical trials to approve annual vaccine booster shots in healthy individuals under 65.

Novavax, Shake Shack, solar stocks: Trending Tickers

Market Domination hosts Josh Lipton and Julie Hyman go over some of the day's top trending tickers. Novavax (NVAX) stock is soaring after the company's COVID-19 vaccine was approved by the US Food and Drug Administration (FDA).